Moderna (MRNA) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 5, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Stephen Hoge, President sold 39,160 shares at $219.66 ($8.6M).
- Trade date
- Nov 16, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All MRNA insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
MRNA insider transactions (Form 4)
Open-market purchases and sales. 139 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | Stephen HogePresident | Sell Plan | 39,1601,673,858 held (−2%) | $219.66 | $8.6M | -8.9% | — |
| Nov 18SEC | Stephen HogePresident | Sell Plan | 33,9761,316,334 held (−3%) | $211.45 | $7.2M | -5.3% | — |
| Nov 18SEC | Stephen HogePresident | Sell Plan | 5,0821,311,252 held (−0%) | $212.57 | $1.1M | -5.8% | — |
| Nov 18SEC | Stephen HogePresident | Sell Plan | 1571,311,095 held (−0%) | $214.19 | $34K | -6.5% | — |
| Oct 16SEC | Stephen HogePresident | Sell Plan | 39,1451,636,565 held (−2%) | $220.72 | $8.6M | -9.3% | — |
| Oct 16SEC | Stephen HogePresident | Sell Plan | 38,7741,599,708 held (−2%) | $213.47 | $8.3M | -6.2% | — |
| Oct 16SEC | Stephen HogePresident | Sell Plan | 4501,599,258 held (−0%) | $214.15 | $96K | -6.5% | — |
| Sep 16SEC | Stephen HogePresident | Sell Plan | 40,2811,562,029 held (−3%) | $146.07 | $5.9M | +37.1% | — |
| Sep 16SEC | Stephen HogePresident | Sell Plan | 40,2941,525,858 held (−3%) | $144.13 | $5.8M | +38.9% | — |
| Sep 14SEC | James M. MockCFO | Sell Plan | 19,83674,375 held (−21%) | $134.49 | $2.7M | +48.9% | — |
| Sep 14SEC | James M. MockCFO | Sell Plan | 15,00059,375 held (−20%) | $134.49 | $2.0M | +48.9% | — |
| Sep 3SEC | Shannon Thyme KlingerGeneral Counsel | Sell Plan | 3,47174,129 held (−4%) | $139.95 | $486K | +43.1% | — |
| Aug 7SEC | Stephane BancelCEO | Sell Plan | 187,0446,187,791 held (−3%) | $58.79 | $11.0M | +240.5% | — |
| Aug 7SEC | Stephane BancelCEO | Sell Plan | 147,4736,539,564 held (−2%) | $56.21 | $8.3M | +256.2% | — |
| Aug 7SEC | Stephane BancelCEO | Sell Plan | 124,8386,414,726 held (−2%) | $56.96 | $7.1M | +251.5% | — |
| Aug 7SEC | Stephane BancelCEO | Sell Plan | 39,8916,374,835 held (−1%) | $58.12 | $2.3M | +244.5% | — |
| Jul 16SEC | Stephen HogePresident | Sell Plan | 53,3361,483,848 held (−3%) | $67.60 | $3.6M | +196.2% | — |
| Jun 17SEC | Stephen HogePresident | Sell Plan | 53,3361,483,848 held (−3%) | $51.37 | $2.7M | +289.7% | — |
| Jun 8SEC | Shannon Thyme KlingerGeneral Counsel | Sell Plan | 3,47167,468 held (−5%) | $50.00 | $174K | +300.4% | — |
| May 22SEC | Noubar AfeyanDirector | Sell | 9,2633,924 held (−70%) | $46.84 | $434K | +327.4% | — |
| May 18SEC | Stephen HogePresident | Sell Plan | 53,3361,477,997 held (−3%) | $48.40 | $2.6M | +313.6% | — |
| May 4SEC | Abbas HussainDirector | Sell Plan | 5,68212,066 held (−32%) | $46.63 | $265K | +329.3% | — |
| Mar 3SEC | Shannon Thyme KlingerGeneral Counsel | Sell Plan | 13,88559,689 held (−19%) | $52.29 | $726K | +282.9% | — |
| Feb 25SEC | Stephen HogePresident | Sell Plan | 160,0091,457,427 held (−10%) | $48.84 | $7.8M | +309.9% | — |
| Dec 15SEC | Noubar AfeyanDirector | Sell | 23,8533,924 held (−86%) | $29.48 | $703K | +579.0% | — |
| Dec 11SEC | Abbas HussainDirector | Sell Plan | 5041,515 held (−25%) | $27.60 | $14K | +625.4% | — |
Similar past setups: not applicable. MRNA has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with MRNA in the Research Lab
MRNA has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Moderna insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $98.5M of MRNA stock on the open market.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
MRNA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $33.9M | 7 |
| Q3 2026 | — | 0 | $49.2M | 10 |
| Q2 2026 | — | 0 | $6.2M | 5 |
| Q1 2026 | — | 0 | $8.5M | 2 |
| Q4 2025 | — | 0 | $717K | 2 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 2, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Moderna insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $98.5M. 24 of 26 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
MRNA earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 6, 2026 | -1.8% | Sold $17.0M | +11.4%S&P +2.7% | pending |
| Jul 31, 2026 | -15.2% | Sold $3.6M | -4.8%S&P +2.2% | +173.5% |
| May 1, 2026 | -15.3% | None | +3.0%S&P -0.1% | +3.7% |
| Feb 13, 2026 | -11.5% | None | +9.5%S&P +0.2% | +19.2% |
| Jan 12, 2026 | +4.7% | None | +15.5%S&P -0.0% | +1.3% |
| Nov 6, 2025 | -14.3% | None | +4.2%S&P -1.0% | +12.9% |
| Aug 1, 2025 | -7.8% | None | -6.5%S&P -0.1% | -13.0% |
| May 1, 2025 | +8.8% | None | -3.3%S&P +2.2% | -3.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
MRNA short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Insiders at Moderna
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Stephen HogePresident | — | $62.3M | Nov 18, 2026 | — | — |
| Stephane BancelCEO | — | $28.7M | Aug 7, 2026 | 0 of 1 | — |
| James M. MockCFO | — | $4.7M | Oct 7, 2026 | — | — |
| Shannon Thyme KlingerGeneral Counsel | — | $1.4M | Sep 8, 2026 | — | — |
| Noubar AfeyanDirector | — | $1.1M | May 22, 2026 | — | — |
| Abbas HussainDirector | — | $279K | May 4, 2026 | — | — |
| Elizabeth E. TallettDirector | — | — | May 4, 2026 | — | — |
| Francois NaderDirector | — | — | May 4, 2026 | — | — |
| Elizabeth G. NabelDirector | — | — | May 4, 2026 | — | — |
| David M. RubensteinDirector | — | — | May 4, 2026 | — | — |
| Sandra HorningDirector | — | — | May 4, 2026 | — | — |
Board links: companies that share insiders with MRNA
Directors and executives who filed Form 4s for MRNA and another company in the last 12 months.
- CGCarlyle Group David M. Rubenstein Director here · Director at CG · latest filing Sep 11, 2026
- GILDGilead Sciences Sandra Horning Director here · Director at GILD · latest filing May 4, 2026
- MDTMedtronic Elizabeth G. Nabel Director here · Director at MDT · latest filing May 4, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
MRNA stock: common questions
Are Moderna insiders buying MRNA stock?
No. No Moderna insider reported an open-market purchase of MRNA in the past 12 months.
Are Moderna insiders selling MRNA stock?
6 insiders reported sales worth $98.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is MRNA's 52-week range?
Over the past year MRNA has traded between $22.36 and $269.00. It last closed at $200.20 on Nov 19, 2026.